Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.

McEnaney PJ, Parker CG, Zhang AX, Spiegel DA.

ACS Chem Biol. 2012 Jul 20;7(7):1139-51. doi: 10.1021/cb300119g. Epub 2012 Jul 3. Review.

2.

Exploring binding and effector functions of natural human antibodies using synthetic immunomodulators.

Jakobsche CE, Parker CG, Tao RN, Kolesnikova MD, Douglass EF Jr, Spiegel DA.

ACS Chem Biol. 2013 Nov 15;8(11):2404-11. doi: 10.1021/cb4004942. Epub 2013 Sep 20.

3.

Immune cells as anti-cancer therapeutic targets and tools.

Johansson M, Tan T, de Visser KE, Coussens LM.

J Cell Biochem. 2007 Jul 1;101(4):918-26. Review.

PMID:
17265430
4.

Reprogramming urokinase into an antibody-recruiting anticancer agent.

Jakobsche CE, McEnaney PJ, Zhang AX, Spiegel DA.

ACS Chem Biol. 2012 Feb 17;7(2):316-21. doi: 10.1021/cb200374e. Epub 2011 Nov 18.

5.

A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.

Zhang AX, Murelli RP, Barinka C, Michel J, Cocleaza A, Jorgensen WL, Lubkowski J, Spiegel DA.

J Am Chem Soc. 2010 Sep 15;132(36):12711-6. doi: 10.1021/ja104591m.

6.

The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer.

Jackson DC, Purcell AW, Fitzmaurice CJ, Zeng W, Hart DN.

Curr Drug Targets. 2002 Apr;3(2):175-96. Review.

PMID:
11958299
7.

[An overview of antibody therapy against cancer].

Taniguchi H, Imai K.

Nihon Rinsho. 2012 Dec;70(12):2087-92. Review. Japanese.

PMID:
23259378
8.

Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer.

Murelli RP, Zhang AX, Michel J, Jorgensen WL, Spiegel DA.

J Am Chem Soc. 2009 Dec 2;131(47):17090-2. doi: 10.1021/ja906844e.

9.

Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Ford CH, Casson AG.

Cancer Chemother Pharmacol. 1986;17(3):197-208. Review.

PMID:
3527466
10.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
11.

Synthetic peptides as vaccines.

Rothbard JB.

Biotechnology. 1992;20:451-65. Review.

PMID:
1600388
12.

Grand challenge commentary: Synthetic immunology to engineer human immunity.

Spiegel DA.

Nat Chem Biol. 2010 Dec;6(12):871-2. doi: 10.1038/nchembio.477.

PMID:
21079593
13.

Engineered antibodies take center stage.

Huston JS, George AJ.

Hum Antibodies. 2001;10(3-4):127-42. Review.

PMID:
11847424
14.

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.

Knutson KL, Disis ML.

Cancer Immunol Immunother. 2005 Aug;54(8):721-8. Epub 2005 Jan 27. Review.

PMID:
16010587
15.

Recruiting dendritic cells to improve antibody therapy of cancer.

Dhodapkar KM, Dhodapkar MV.

Proc Natl Acad Sci U S A. 2005 May 3;102(18):6243-4. Epub 2005 Apr 25. No abstract available.

16.

An antibody-recruiting small molecule that targets HIV gp120.

Parker CG, Domaoal RA, Anderson KS, Spiegel DA.

J Am Chem Soc. 2009 Nov 18;131(45):16392-4. doi: 10.1021/ja9057647.

17.

The impact of new technologies on vaccine development.

Winther MD, Dougan G.

Biotechnol Genet Eng Rev. 1984;2:1-39. Review.

PMID:
6085856
19.

Augmentation of cellular immune response by Ipomoea obscura and Ipobscurine alkaloid attenuates tumor growth in mice.

Hamsa TP, Kuttan G.

Can J Physiol Pharmacol. 2011 Apr;89(4):259-68. doi: 10.1139/Y11-017. Epub 2011 Apr 13.

PMID:
21539469
20.

Targeted immunotherapy of cancer: development of antibody-induced cellular immunity.

Lu Y, Low PS.

J Pharm Pharmacol. 2003 Feb;55(2):163-7. Review.

PMID:
12635651
Items per page

Supplemental Content

Write to the Help Desk